克莱尔赛德生物医学公司对湿性AMD治疗的2b期试验CLS- AX报告了积极的结果,优于阿弗利伯塞普. Clearside Biomedical's Phase 2b trial for wet AMD treatment CLS-AX reported positive outcomes, outperforming aflibercept.

克莱尔赛德生物医学公司对CLS- AX进行的ODYSSEY 2b期试验,该试验是针对湿性与年龄相关的斑点退化症的注射治疗,报告了积极的结果,实现了主要和次要目标. Clearside Biomedical's ODYSSEY Phase 2b trial for CLS-AX, an injectable treatment for wet age-related macular degeneration, reported positive outcomes, achieving both primary and secondary goals. CLS-AX 保持稳定的最佳矫正视力和眼部解剖结构长达 6 个月，优于阿柏西普。 CLS-AX maintained stable best corrected visual acuity and ocular anatomy for up to 6 months, outperforming aflibercept. 治疗显示,安全情况良好,没有发生严重不良事件。 The treatment showed a well-tolerated safety profile with no serious adverse events. 宣布之后, Clearside的股票涨了25%以上。 Following the announcement, Clearside's stock rose over 25%.